Vor Biopharma Completes $42 Million Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia

Financing led by 5AM Ventures and RA Capital Management

Participation from Johnson & Johnson Innovation – JJDC, Novartis
Institutes for BioMedical Research, Osage University Partners, and Vor
Co-founder PureTech Health

, an immuno-oncology company pioneering engineered
hematopoietic stem cell (HSC) therapies for the treatment of
hematological malignancies, today announced a $42 million Series A
financing round led by 5AM Ventures and RA Capital Management. Johnson &
Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for
BioMedical Research (NIBR), and Osage University Partners also
participated in the round along with Vor Co-founder PureTech Health. Vor
plans to use the proceeds from the financing to advance its lead
HSC-based candidate for the treatment of acute myeloid leukemia (AML)
towards the clinic, and to further build its pipeline to treat
hematologic malignancies.

“Vor’s unique and patented technology platform for enabling targeted
immunotherapies using engineered HSCs has the potential to disrupt the
treatment landscape for hematologic malignancies,” said Kush Parmar,
M.D., Ph.D., Managing Partner at 5AM Ventures who has joined the Vor
Biopharma Board of Directors as Executive Chair. “We are excited to work
with Vor to drive this next chapter of growth forward.”

“The need for new therapies for hematologic malignancies is dire. I am
gratified that this discovery from my lab continues to advance towards
the clinic. This new platform may enable more patients to benefit from
the life-saving potential of targeted immunotherapies,” said Siddhartha
Mukherjee, M.D., D.Phil, Vor Co-founder and Associate Professor of
Medicine at Columbia University. “I look forward to further engaging
with the scientific community when we publish our results in
peer-reviewed journals.”

“We are excited about Vor’s bold and novel approach to potentially
revolutionize the way stem cell transplants are used to treat severe
hematologic cancers,” said Joshua Resnick, M.D., Managing Director at RA
Capital who has also joined the Vor Biopharma Board of Directors.

Vor’s engineered HSC technology platform is designed to address
fundamental limitations of today’s immunotherapies. Vor’s approach has
the potential to expand the reach of targeted immunotherapies to a broad
range of patient populations and hematological malignancies by enabling
new dosing paradigms for cancer-targeted immunotherapies, which can
substantially improve the therapeutic window for efficacy and improve
patient safety.

“We are delighted to welcome this terrific syndicate of investors, who
share our passion, commitment, and vision for bringing Vor’s potentially
life-saving new therapies to patients with acute myeloid leukemia and
other hematologic malignancies,” said Bharatt Chowrira, J.D., Ph.D.,
Board of Directors at Vor Biopharma and President and Chief of Business
& Strategy at PureTech Health.

About Vor Biopharma

Co-founded by PureTech Health (LSE: PRTC) and based on the pioneering
work of Siddhartha
, M.D., D.Phil, as well as Vor’s own intellectual property,
Vor is developing a proprietary pipeline of best-in-class
immunotherapies for patients. The Company is working with some of the
world’s leading oncologists and immunologists including Hans-Peter Kiem,
M.D., Ph.D., the Fred Hutch Endowed Chair for Cell and Gene Therapy and
the Director of the Stem Cell and Gene Therapy Program at the Fred
Hutchinson Cancer Research Center and a Professor of Medicine at the
University of Washington School of Medicine; Dan Littman, M.D., Ph.D.,
the Kimmel Professor of Molecular Immunology at the Skirball Institute
and an Investigator of the Howard Hughes Medical Institute at NYU
Langone Health; Derrick J. Rossi, Ph.D., an Associate Professor in the
Stem Cell and Regenerative Biology Department at Harvard Medical School
and Harvard University; and Joseph Bolen, Ph.D., Chief Scientific
Officer at PureTech Health.


Allison Mead Talbot
+1 617 651 3156

US media
Tom Donovan
+1 857 559 3397

error: Content is protected !!